CellCept (mycophenolate mofetil) plus low-dose tacrolimus, corticosteroids and IL-2 induction therapy was shown to be the top combination to prevent patients rejecting their new kidney whilst ...

CellCept is a prescription drug used to help prevent organ rejection after a transplant. Learn about the drug’s dosages, forms, strengths, and more.

CellCept is a prescription drug used to help prevent organ rejection. Learn about the common, mild, and serious side effects it can cause and how to manage them.

The study compared a regimen of mycophenolate mofetil (MMF; Cellcept) plus sirolimus and a regimen of MMF plus a CNI (either tacrolimus or cyclosporine) in 298 renal transplant recipients.

CellCept is a prescription drug used to help prevent organ rejection after an organ transplant. Learn about the drug’s possible side effects and how to manage them.

CellCept, the largest selling branded immunosuppressant in North America, offers both physicians and patients the possibility of an effective long-term immunosuppressant regimen with low toxicity.

They were randomized to receive obinutuzumab, 1,000 mg or placebo on background standard therapy of 2 to 2.5 g mycophebnolate mofetil (CellCept) plus an initial pulse of 1 to 3 g ...

SAN FRANCISCO (MarketWatch) -- Aspreva Pharmaceuticals Corp. late Wednesday said the Food and Drug Administration has granted fast-track designation for CellCept for the treatment of lupus nephritis.

The Food and Drug Administration (FDA) has expanded the approval of CellCept (mycophenolate mofetil) to include prophylaxis of organ rejection in pediatric recipients of allogeneic heart and liver ...

Adding voclosporin to CellCept therapy also resulted in more patients achieving at least a partial response. In the two-drug combination, the partial response rate was 68% in the 23.7 mg dose arm.

Learn about the dosages for CellCept in preventing organ rejection following transplant. You can also find information on the drug’s strengths, forms, and more.